Relafen 750, pharmacologically known as naproxen, represents a noteworthy case study from a biochemical pharmacy standpoint. The drug exhibits its medicinal effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin formation. The specific inhibition of COX-2, compared to traditio